PROCESSED AT :
Thyrocare

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

MC-2407

Thyrocare
Tests you can trust

Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400703 98706 66333 wellness@thyrocare.com

*9 out of 10 Doctors Trust that Thyrocare Reports are **Accurate & Reliable***

NAME : XXXXXXXXXXXXXXXXX
REF. BY : XXXXXXXXXXXXXXXXX
TEST ASKED : CA 15.3

SAMPLE COLLECTED AT :
XXXXXXXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS
CA 15.3	C.M.I.A	7.7	U/mL

Bio. Ref. Interval. :-

Less than 32.4 U/ml

Clinical Significance:
CA 15.3 is elevated in about 30% of women with localized breast cancer and in about 75% of those with metastatic breast cancer. CA 15.3 also may be elevated in Healthy people and in individuals with other cancers or diseases, Such as Colorectal Cancer, Lung Cancer, Cirrhosis, Hepatitis, and Benign Breast Disease. In General, the higher the CA 15-3 level the more advanced the Breast Cancer and the larger the Tumor Burden.

Specifications:
Precision: Intra Assay (%CV): 3.7 %, Inter Assay (%CV): 2.2 %; Sensitivity:<=0.5 U/ml

Kit Validation References:
eddish MA, Helbrecht N, Almeida AF, ET AL. Epitope mapping of MAB B27.29 Within the peptide core for the Malignant Breast Varcinoma-Associated mucin antigen coded for by the human Muc-1 Gene. J Tumor Marker Oncol. 1992, 7:19-27.

Please correlate with clinical conditions.
Method:- FULLY AUTOMATED CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY

~~ End of report ~~

Dummy Report

Sample Collected on (SCT) : Sample collection time
Sample Received on (SRT) : Sample receiving time at Lab
Report Released on (RRT) : Report release time
Sample Type : SERUM
Labcode :
Barcode :

Doctor 1 Sign Doctor 2 Sign